Peplin Limited Company Profile

05:23 EDT 23rd March 2018 | BioPortfolio

Peplin Limited (Peplin) is a public company focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Peplin is listed on the Australian Stock Exchange (ASX:PEP) and has approximately 127 million shares on issue owned by over 3,000 shareholders. The company is based in Brisbane, Queensland, Australia. Peplin's core technology is a novel class of naturally occurring compounds which show significant potential as anti-cancer agents for a wide range of human cancers. The lead compound in this technology (PEP005) has demonstrated significant promise in a phase IIa clinical trial for actinic keratosis (AK) and in a pilot clinical trial as a topical agent against non-melanoma skin cancer conducted in 1999-2002. Peplin has extensive international patent coverage over its technologies.Peplin's vision is to deliver superior returns to shareholders through a focus on developing and commercialising products for the global market. Peplin's initial goal is to dominate the skin cancer market by delivering a novel product for the treatment of skin cancer.
Peplin will build on that foundation to deliver market leading products for other types of cancer. Peplin's strategy is to accomplish the majority of its commercialisation activities at least for its lead product through collaborative arrangements with leading international pharmaceutical companies. As a component of its growth and development it will seek to participate in higher value downstream segments of the product


Level 2Brisbane Portal
1 Breakfast Creek Road
Brisbane Queensland


Fax: 61-7-3250 1299 / (07) 3250 1299

News Articles [30 Associated News Articles listed on BioPortfolio]

Genetic Technologies Limited: Update on Strategic Alliance

MELBOURNE, Australia, Feb. 12, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG) (NASDAQ:GENE) (“Company”, “GTG”), wishes to advise that the Company is presently in discussi...

Appointment of Director

Oxford, UK, 1 November 2017: e-Therapeutics plc (AIM: ETX), a company pioneering the use of Network-Driven Drug Discovery (NDD) to create new and better drugs, announces the appointment of Christine...

Telix Pharmaceuticals Limited Lists on the Australian Securities Exchange

MELBOURNE, Australia, Nov. 15, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the developmen...

Genetic Technologies Limited: Project Shivom Strategic Alliance

MELBOURNE, Australia, March 06, 2018 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX:GTG)  (NASDAQ:GENE) (“Company”, “GTG”) a diversified molecular diagnostics company; provider of...

Quotient Limited Announces Appointment of Franz Walt as Non-Executive Director

JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of...

Quotient Limited Reports Second Quarter Fiscal 2018 Financial Results

MosaiQ project de-risked, Verification and Validation (“V&V”) “head-to-head” studies confirm targeted concordance levels for all blood grouping assaysEuropean field trials planned to co...

Quotient Limited to Participate in the Jefferies 2017 London Healthcare Conference

JERSEY, Channel Islands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Execut...

Immutep Limited Announces Milestone Payment From Chinese Partner EOC Pharma

SYDNEY, Australia, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Immutep Limited (ASX:IMM) (NASDAQ:IMMP) announced today that it has received a milestone payment from the Company’s Chinese partner for efti...

PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [84 Associated Companies listed on BioPortfolio]

Peplin Limited

Peplin Limited (Peplin) is a public company focused on the development and commercialisation of prescription human therapeutic products for the treatment of cancer. Peplin is listed on the Australian ...

Peplin, Inc.

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

Immunocore Limited

Immunocore Limited is developing innovative biological therapeutics to treat a range of cancers, chronic viral infections and diabetes. Immunocore is a privately owned biotechnology company located ...


More Information about "Peplin Limited" on BioPortfolio

We have published hundreds of Peplin Limited news stories on BioPortfolio along with dozens of Peplin Limited Clinical Trials and PubMed Articles about Peplin Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Peplin Limited Companies in our database. You can also find out about relevant Peplin Limited Drugs and Medications on this site too.

Quick Search


Relevant Topics

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Corporate Database Quicklinks

Searches Linking to this Company Record